This page is being served from the Urological Sciences Research Foundation web repository, and was originally posted between 1996-2008. In January 2009 USRF’s founder, Dr. Leonard S. Marks and his staff joined UCLA’s Department of Urology where they are continuing their research. Click for more information.

Rountable Conference
Arie Belldegrun, M.D.
UCLA School of Medicine
10833 Le Conte Avenue
CHS 66-118, Div. Of Urology
Los Angeles, CA 90095-1738
Phone: (310) 206-1434
E-mail: abelldegrun@mednet.ucla.edu
Slides
play Modem || Broadband Real Media
Arie Belldegrun, M.D.

Arie Belldegrun, MD is Chief of the Division of Urologic Oncology and Director of Urologic Research in the Department of Urology at the University of California, Los Angeles. He is a UCLA Professor of Urology, Clinical Director of the UCLA Prostate Disease Research Program and Surgical Director of the UCLA Kidney Cancer Program. He is also the Founder and Chairman of the Board of Agensys, Inc., a privately held biotechnology company focusing on the discovery and development of novel and innovative products for the diagnosis and treatment of urological diseases. He has also been appointed as a member of the Governor's Council on Bioscience.

He completed his medical degree at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate fellowship at the Weizmann Institute of Science and his residency in Urology at Harvard Medical School. Prior to UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology under Steven A. Rosenberg, MD, PhD. Certified by the American Board of Urology and a Fellow of the American College of Surgeons, Dr. Belldegrun is licensed to practice in California, New York, Virginia, Massachusetts and Israel.

In addition to running an extremely busy urologic oncology surgery practice, Dr. Belldegrun is involved in many national and international cancer and biotechnology related committees, serves on several advisory panels with such organizations as the National Institutes for Health and Department of Defense and serves on several editorial boards. He is also on several scientific boards of biotechnology and pharmaceutical companies and serves as a reviewer for many medical journals and granting organizations. In addition to holding several patents, Dr. Belldegrun is the author of several books on prostate and kidney cancers and has written over 250 scientific publications with an emphasis on urologic oncology, particularly kidney, prostate and bladder cancers.

Dr. Belldegrun is married to Dr. Rebecka Belldegrun, president of Intertech Corp., and has four children.